Zobrazeno 1 - 10
of 61
pro vyhledávání: '"B. Ostermann"'
Autor:
Bing Z. Carter, Po Yee Mak, Wenjing Tao, Edward Ayoub, Lauren B. Ostermann, Xuelin Huang, Sanam Loghavi, Steffen Boettcher, Yuki Nishida, Vivian Ruvolo, Paul E. Hughes, Phuong K. Morrow, Torsten Haferlach, Steven Kornblau, Muharrem Muftuoglu, Michael Andreeff
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-13 (2023)
Abstract TP53-mutant acute myeloid leukemia (AML) respond poorly to currently available treatments, including venetoclax-based drug combinations and pose a major therapeutic challenge. Analyses of RNA sequencing and reverse phase protein array datase
Externí odkaz:
https://doaj.org/article/ed4c5f0838c540e4bdf8c2b8285492df
Autor:
Bing Z. Carter, Po Yee Mak, Wenjing Tao, Lauren B. Ostermann, Duncan H. Mak, Baozhen Ke, Peter Ordentlich, Gerard M. McGeehan, Michael Andreeff
Publikováno v:
Haematologica, Vol 108, Iss 9 (2023)
Externí odkaz:
https://doaj.org/article/4453f8a7c7cb41ef82656e6e82749de1
Autor:
Eric Haines, Yuki Nishida, Michael I. Carr, Rafael Heinz Montoya, Lauren B. Ostermann, Weiguo Zhang, Frank T. Zenke, Andree Blaukat, Michael Andreeff, Lyubomir T. Vassilev
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-14 (2021)
Abstract Peposertib (M3814) is a potent and selective DNA-PK inhibitor in early clinical development. It effectively blocks non-homologous end-joining repair of DNA double-strand breaks (DSB) and strongly potentiates the antitumor effect of ionizing
Externí odkaz:
https://doaj.org/article/36b7c6a88d6e4d8b9b33159cd731cb9e
Autor:
Bing Z. Carter, Po Yee Mak, Wenjing Tao, Edward Ayoub, Lauren B. Ostermann, Xuelin Huang, Sanam Loghavi, Steffen Boettcher, Yuki Nishida, Vivian Ruvolo, Paul E. Hughes, Phuong K. Morrow, Torsten Haferlach, Steven Kornblau, Muharrem Muftuoglu, Michael Andreeff
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-1 (2023)
Externí odkaz:
https://doaj.org/article/3a3640a997424898be13fe344335ea7a
Autor:
Sean M. Post, Huaxian Ma, Prerna Malaney, Xiaorui Zhang, Marisa J.L. Aitken, Po Yee Mak, Vivian R. Ruvolo, Tomoko Yasuhiro, Ryohei Kozaki, Lauren E. Chan, Lauren B. Ostermann, Marina Konopleva, Bing Z. Carter, Courtney DiNardo, Michael D. Andreeff, Joseph D. Khoury, Peter P. Ruvolo
Publikováno v:
Haematologica, Vol 107, Iss 6 (2021)
FMS-like Tyrosine Kinase 3 (FLT3) mutation is associated with poor survival in acute myeloid leukemia (AML). The specific Anexelekto/MER Tyrosine Kinase (AXL) inhibitor, ONO-7475, kills FLT3-mutant AML cells with targets including Extracellular- sign
Externí odkaz:
https://doaj.org/article/48b85cbe0a1047eaba094b35a51665e8
Autor:
B. Ostermann, T. Warnecke
Publikováno v:
DGNeurologie. 5:120-123
Autor:
Rasoul Pourebrahim, Rafael Heinz Montoya, Edward Ayoub, Hiroki Akiyama, Natalia Baran, Tom Lesluyes, Lauren B Ostermann, Bin Liu, Jo Ishizawa, Joseph D. Khoury, Marina Konopleva, Peter Van Loo, Michael Andreeff
Publikováno v:
Blood. 140:5876-5878
Autor:
Joseph D. Khoury, Prerna Malaney, Courtney D. DiNardo, Bing Z. Carter, Lauren B Ostermann, Michael Andreeff, Ryohei Kozaki, Xiaorui Zhang, Marina Konopleva, Sean M. Post, Marisa J.L. Aitken, Peter P. Ruvolo, Huaxian Ma, Vivian Ruvolo, Tomoko Yasuhiro, Po Yee Mak, Lauren E. Chan
Publikováno v:
Haematologica. 107:1311-1322
FMS-like Tyrosine Kinase 3 (FLT3) mutation is associated with poor survival in acute myeloid leukemia (AML). The specific Anexelekto/MER Tyrosine Kinase (AXL) inhibitor, ONO-7475, kills FLT3-mutant AML cells with targets including Extracellular- sign
Autor:
Gerard McGeehan, Lauren B Ostermann, Peter Ordentlich, Bing Z. Carter, Duncan H. Mak, Wenjing Tao, Po Yee Mak, Michael Andreeff
Publikováno v:
Blood
Autor:
Bing Carter, Po Yee Mak, Wenjing Tao, Lauren B Ostermann, Yuki Nishida, Steffen Boettcher, Michael Andreeff
Publikováno v:
Blood Cancer Discovery. 4:A08-A08
The Bcl-2 inhibitor venetoclax (VEN)/hypomethylation agent (HMA) combination achieves high response rates, has improved outcomes for many patients with AML and is now considered standard of care for patients who are older or unfit to receive intensiv